Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.100
+0.060 (2.94%)
At close: Oct 24, 2024, 4:00 PM
2.090
-0.010 (-0.48%)
After-hours: Oct 24, 2024, 4:39 PM EDT

Cellectar Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Mar '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
13.3210.759.596.545.155.18
Upgrade
Research & Development
28.9428.2119.2217.5910.149
Upgrade
Operating Expenses
42.2638.9628.8124.1315.2914.18
Upgrade
Operating Income
-42.26-38.96-28.81-24.13-15.29-14.18
Upgrade
Interest & Investment Income
0.580.390.1500.010.04
Upgrade
Other Non Operating Income (Expenses)
-9.370.53-0.01-0.04
Upgrade
EBT Excluding Unusual Items
-51.04-38.04-28.66-24.12-15.28-14.09
Upgrade
Other Unusual Items
----0.19-
Upgrade
Pretax Income
-51.04-38.04-28.66-24.12-15.09-14.09
Upgrade
Income Tax Expense
-0.06-0.06-0.06---
Upgrade
Net Income
-50.98-37.98-28.6-24.12-15.09-14.09
Upgrade
Net Income to Common
-50.98-37.98-28.6-24.12-15.09-14.09
Upgrade
Shares Outstanding (Basic)
17127621
Upgrade
Shares Outstanding (Diluted)
17127621
Upgrade
Shares Change (YoY)
100.67%73.22%27.09%180.20%158.14%159.12%
Upgrade
EPS (Basic)
-3.05-3.11-4.05-4.35-7.62-18.36
Upgrade
EPS (Diluted)
-3.05-3.11-4.05-4.35-7.62-18.36
Upgrade
Free Cash Flow
-39.44-33.24-25.45-22.71-14-11.72
Upgrade
Free Cash Flow Per Share
-2.36-2.72-3.61-4.09-7.06-15.27
Upgrade
EBITDA
-42.02-38.77-28.67-23.98-15.15-14.05
Upgrade
D&A For EBITDA
0.240.190.150.150.140.13
Upgrade
EBIT
-42.26-38.96-28.81-24.13-15.29-14.18
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.